These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20824037)

  • 1. Male Breast Cancer.
    Rudlowski C
    Breast Care (Basel); 2008; 3(3):183-189. PubMed ID: 20824037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding and management of male breast cancer: a critical review.
    Pant K; Dutta U
    Med Oncol; 2008; 25(3):294-8. PubMed ID: 18074245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
    Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
    Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responding to the challenges of breast cancer in egypt and other arab countries.
    El Saghir NS
    J Egypt Natl Canc Inst; 2008 Dec; 20(4):309-12. PubMed ID: 20571588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of male triple negative breast cancer: A population-based study.
    Ghani S; Sochat M; Luo J; Tao Y; Ademuyiwa F
    Breast J; 2020 Sep; 26(9):1748-1755. PubMed ID: 32856383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer in men.
    Giordano SH; Buzdar AU; Hortobagyi GN
    Ann Intern Med; 2002 Oct; 137(8):678-87. PubMed ID: 12379069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.
    Araki K; Saji S; Gallas M; Pegram M; Sasaki Y
    Breast Cancer; 2012 Apr; 19(2):95-103. PubMed ID: 21863310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.
    de Blok CJM; Wiepjes CM; Nota NM; van Engelen K; Adank MA; Dreijerink KMA; Barbé E; Konings IRHM; den Heijer M
    BMJ; 2019 May; 365():l1652. PubMed ID: 31088823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute.
    Anderson WF; Devesa SS
    Cancer; 2005 Oct; 104(8):1733-41. PubMed ID: 16138363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
    Sammons S; Sedrak MS; Kimmick GG
    Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17.
    Oliver RT
    Oncologist; 1996; 1(4):278-279. PubMed ID: 10388003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.